Age-Related Macular Degeneration (AMD) is the leading cause of irreversible blindness in the developed world, robbing older individuals of their sight and autonomy. New treatments have transformed lives for patients with “wet” AMD, but benefit just 15% of all patients with late-stage disease.  Unfortunately, “dry” AMD is the underlying form of disease, affecting 100% of patients, and new treatments for late dry AMD that are both safe & efficacious in the real world, are only now emerging.  As new treatments become available, Tracery’s mission is to ensure that different therapies are optimally applied to each patient, maximizing vision and limiting potential side effects.

Tracery’s imaging and analytics platform is designed to assist eye care practitioners, pharma, and translational researchers with multi-modal ophthalmic imaging, cross-modal ML/AI support, and the development of novel imaging biomarkers based on our own unique imaging method.  We are committed to optimizing care.